These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 34923180)

  • 1. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
    Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
    Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
    Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
    Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of bevacizumab administered prior to transarterial chemoembolization on the therapeutic effects of lenvatinib given post-TACE in primary liver cancer patients.
    Dang Z; Jiang L; Huang F
    Int J Clin Pharmacol Ther; 2023 Oct; 61(10):423-429. PubMed ID: 37548453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.
    Guo Y; Ren Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    BMC Cancer; 2022 Mar; 22(1):270. PubMed ID: 35287627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Fufang Banmao Capsule Associated with Sorafenib on Liver Function, Immune Status, Quality of Life Improvement, and Survival in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
    Lai X; Wang A
    Comput Intell Neurosci; 2022; 2022():6336107. PubMed ID: 36052044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
    Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients.
    Zhu C; Dai B; Zhan H; Deng R
    Ir J Med Sci; 2023 Jun; 192(3):1065-1071. PubMed ID: 35996068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of TACE Combined with Regorafenib versus TACE Combined with Camrelizumab in Hepatocellular Carcinoma With Untreatable Progression After TACE Combined with Sorafenib Therapy: A Case Control Study.
    Ren Y; Liu Y; Song S; Zheng C
    Cancer Control; 2024; 31():10732748241275004. PubMed ID: 39163892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
    Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
    Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy of aparatinib and carrilizumab combined with transcatheter arterial chemoembolization in the treatment of primary hepatocellular carcinoma.
    Chen C; Duan XT; Li GY; Hao XJ; Wang WL; Shen YF; Zhang SH
    Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4135-4144. PubMed ID: 37203839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
    Ren Y; Liu Z; Makamure J; Kan X; Song S; Liu Y; Qian K; Zheng C; Liang B
    Technol Cancer Res Treat; 2022; 21():15330338221131385. PubMed ID: 36259117
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis.
    Xian F; Song XW; Bie J; Zhao CX; Zhang GJ; Xu GH
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):687-701. PubMed ID: 38305611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial.
    Hao Y; Xie F; Zhou Y; Li C; Zhang X; Shen J; Yao M; Sun X; Zhou J; Wen T; Peng W
    Trials; 2024 Jul; 25(1):490. PubMed ID: 39030637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
    Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
    Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center.
    Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    Can J Gastroenterol Hepatol; 2022; 2022():7982118. PubMed ID: 35586608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
    Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
    Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propensity score matching analysis of efficacy of drug-eluting beads (DEB)-TACE loaded with different drugs in the treatment of hepatocellular carcinoma.
    Yang L; Wang H; Li S; Gan G; Deng W; Chang Y; Zhang L
    Am J Transl Res; 2023; 15(2):1526-1532. PubMed ID: 36915718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.